据SELLAS报道,新型AML治疗的结果令人期待, SELLAS reports promising results for new AML treatment, showing improved survival rates.

SELLAS生命科学小组宣布了第二阶段SLS009试验的积极成果,SLS009是一种CDK9抑制剂,用于复发性/抗性急性流质性白血病(AML)。 SELLAS Life Sciences Group announced positive results from a Phase 2 trial of SLS009, a CDK9 inhibitor, for relapsed/refractory acute myeloid leukemia (AML). 接受试验的病人显示,总体存活率中位数为8.8至8.9个月,大大高于2.5个月的历史基准。 Patients in the trial showed a median overall survival of 8.8 to 8.9 months, significantly higher than the historical benchmark of 2.5 months. 总体应答率达到46%,其中有67%为肌肉形相关变化的AML患者. The overall response rate reached 46%, with 67% for AML patients with myelodysplasia-related changes. 药物耐受性良好,公司预计在2025年上半年将获得完整的数据和FDA反. The drug was well-tolerated, and the company expects full data and FDA feedback in the first half of 2025.